In this manuscript three areas of investigation are conducted; first, we test whether α2M complexed to a bulk preparation of tumor-derived peptides (representing the entire antigenic repertoire of the tumor) can be used in therapy of established tumors in mice, circumventing the identification of tumor specific antigens. Here, A2M is linked to neoplasm.